OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SIPE.PSX55

Sitara Peroxide Ltd

Commodity ChemicalsVerified

Sitara Peroxide Ltd's capital structure is characterized by a debt-to-equity ratio of 0.44, indicating a relatively conservative leverage position. However, the company's liquidity is constrained, as evidenced by a current ratio of 0.39, which is below the typical threshold of 1.0 for healthy liquidity. The company reported negative operating cash flow of PKR -8.28 million and free cash flow of PKR -21.68 million, signaling cash flow challenges. Profitability metrics are deeply negative, with a return on equity of -5.08% and a return on assets of -1.92%. These figures are well below the industry median for Commodity Chemicals, which typically sees positive returns in stable market conditions. The company's operating income of PKR -57.12 million and net income of PKR -60.19 million further underscore its unprofitable operations. The company's revenue is not disclosed in the latest financials, but its geographic exposure is concentrated in Pakistan, with no material international operations reported. This concentration increases vulnerability to local economic and regulatory shifts. No segment-specific revenue breakdown is available, but the company's primary business is peroxide production, which is a niche but essential industrial chemical. Growth trajectory is negative, with no revenue reported in the latest period and a lack of historical data to establish a trend. The company's operating income and net income have deteriorated significantly, with no clear signs of recovery in the near term. The outlook for the current fiscal year is weak, with no positive momentum in key financial metrics. Risk factors include liquidity constraints and negative cash flow generation. The company's net cash position is negative after subtracting total debt, raising concerns about its ability to meet short-term obligations. Dilution risk is currently low, as there is no indication of share issuance or dilution pressure in the latest filings. However, the company's financial instability could lead to future capital-raising activities that may dilute existing shareholders. Recent events include the filing of the latest financial report, which reveals the company's unprofitable position and liquidity challenges. No recent earnings call transcripts or material regulatory filings are available to provide additional context on the company's strategic direction or operational performance.

30-day price · SIPE.PSX+35.50 (+102.9%)
Low$33.50High$87.41Close$70.00As of15 May, 00:00 UTC
Profile
CompanySitara Peroxide Ltd
TickerSIPE.PSX
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Sitara Peroxide Ltd is a chemical manufacturing company that produces and sells peroxides and related chemical products, primarily serving industrial and consumer markets in Pakistan.

Classification. Sitara Peroxide Ltd is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a high confidence level of 0.92 based on verified market data.

Sitara Peroxide Ltd's capital structure is characterized by a debt-to-equity ratio of 0.44, indicating a relatively conservative leverage position. However, the company's liquidity is constrained, as evidenced by a current ratio of 0.39, which is below the typical threshold of 1.0 for healthy liquidity. The company reported negative operating cash flow of PKR -8.28 million and free cash flow of PKR -21.68 million, signaling cash flow challenges. Profitability metrics are deeply negative, with a return on equity of -5.08% and a return on assets of -1.92%. These figures are well below the industry median for Commodity Chemicals, which typically sees positive returns in stable market conditions. The company's operating income of PKR -57.12 million and net income of PKR -60.19 million further underscore its unprofitable operations. The company's revenue is not disclosed in the latest financials, but its geographic exposure is concentrated in Pakistan, with no material international operations reported. This concentration increases vulnerability to local economic and regulatory shifts. No segment-specific revenue breakdown is available, but the company's primary business is peroxide production, which is a niche but essential industrial chemical. Growth trajectory is negative, with no revenue reported in the latest period and a lack of historical data to establish a trend. The company's operating income and net income have deteriorated significantly, with no clear signs of recovery in the near term. The outlook for the current fiscal year is weak, with no positive momentum in key financial metrics. Risk factors include liquidity constraints and negative cash flow generation. The company's net cash position is negative after subtracting total debt, raising concerns about its ability to meet short-term obligations. Dilution risk is currently low, as there is no indication of share issuance or dilution pressure in the latest filings. However, the company's financial instability could lead to future capital-raising activities that may dilute existing shareholders. Recent events include the filing of the latest financial report, which reveals the company's unprofitable position and liquidity challenges. No recent earnings call transcripts or material regulatory filings are available to provide additional context on the company's strategic direction or operational performance.
Key takeaways
  • Sitara Peroxide Ltd is operating at a significant loss, with negative operating and net income.
  • The company's liquidity is weak, with a current ratio of 0.39 and negative operating cash flow.
  • Return on equity and return on assets are deeply negative, indicating poor capital efficiency.
  • The company's geographic and product concentration increases its vulnerability to local market conditions.
  • No clear signs of recovery or growth are evident in the latest financial data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue$0.00
Gross profit-$40.9M
Operating income-$57.1M
Net income-$60.2M
R&D
SG&A
D&A
SBC
Operating cash flow-$8.3M
CapEx
Free cash flow-$21.7M
Total assets$3.14B
Total liabilities$1.96B
Total equity$1.18B
Cash & equivalents
Long-term debt$515.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.87B$13.7M$34.7M-$4.2M
FY-3$1.74B-$387.0M-$341.2M-$114.6M
FY-2$824.0M-$753.3M-$792.8M-$613.5M
FY-1$14.9M-$305.5M-$169.4M$14.5M
FY0$0.00-$311.4M-$222.5M-$42.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$4.09B$2.47B
FY-3$3.91B$2.14B
FY-2$3.44B$1.32B
FY-1$3.06B$1.21B
FY0$2.78B$989.1M
PeriodOCFCapExFCFSBC
FY-4$276.8M-$223.0M-$4.2M
FY-3$7.3M-$3.6M-$114.6M
FY-2-$194.8M-$8.6M-$613.5M
FY-1-$5.1M$0.00$14.5M
FY0$19.7M-$42.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$57.1M-$60.2M-$21.7M
FQ-6$0.00-$116.6M-$32.8M$36.0M
FQ-5$0.00-$81.5M-$70.8M-$25.0M
FQ-4$0.00-$66.5M-$53.0M-$7.3M
FQ-3$0.00-$52.6M-$52.6M-$6.5M
FQ-2$0.00-$110.9M-$77.6M-$34.9M
FQ-1$0.00-$61.4M-$49.5M-$5.1M
FQ0$272.5M$297.4M$342.6M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$3.14B$1.18B
FQ-6$3.06B$1.21B
FQ-5$3.02B$1.14B
FQ-4
FQ-3$2.91B$1.07B
FQ-2$2.78B$989.1M
FQ-1$2.74B$939.5M
FQ0$2.65B$1.22B
PeriodOCFCapExFCFSBC
FQ-7-$8.3M-$21.7M
FQ-6-$5.1M$0.00$36.0M
FQ-5$24.9M-$25.0M
FQ-4$16.6M-$7.3M
FQ-3-$6.7M-$6.5M
FQ-2$19.7M-$34.9M
FQ-1$5.5M-$5.1M
FQ0-$77.1M$342.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.18B
Net cash-$515.5M
Current ratio0.4
Debt/Equity0.4
ROA-1.9%
ROE-5.1%
Cash conversion14.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricSIPE.PSXActivity
Op margin5.5% medp25 -0.0% · p75 10.8%
Net margin4.1% medp25 0.1% · p75 8.8%
Gross margin20.5% medp25 12.4% · p75 29.7%
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-6.2% medp25 -13.4% · p75 -2.6%
Debt / equity44.0%37.1% medp25 10.3% · p75 82.0%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 01:21 UTC#15aed97a
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 10:57 UTCJob: 410d37d5